Re Alessia, Lai Sebastiana, Mantione Glenda, D'Aviero Andrea, Sanna Fabrizio, Pilloni Elisa, Menna Sebastiano, Piccari Danila, Boschetti Althea, Fionda Bruno, Porru Davide, Tramaloni Pierangela, Gallus Roberto, Tagliaferri Luca, Montesu Maria Antonietta, Rubino Corrado, Bussu Francesco, Mattiucci Gian Carlo
Radiation Oncology, Mater Olbia Hospital, 07100 SassariOlbia, Italy.
Division of Otolaryngology, Azienda Ospedaliera Universitaria, 07100 Sassari, Italy.
J Clin Med. 2025 May 9;14(10):3305. doi: 10.3390/jcm14103305.
: High-dose-rate (HDR) interventional radiotherapy (IRT) represents a valuable treatment alternative for basal cell carcinoma (BCC) of the midface, especially in the presence of esthetic or functional issues related to surgery. This retrospective study examines the clinical outcomes of patients who underwent HDR-IRT at our institution. : Patients (pts) with histologically confirmed midface BCC were treated with HDR-IRT using superficial, interstitial, or endocavitary implants depending on tumor characteristics. Fractionation regimens were tailored to tumor location: 45 Gy in 9 fractions twice a day (the cheeks/lips) and 44 Gy in 14 fractions (the nose, with the first and last fractions delivering 4 Gy each, administered once daily, and the remaining 12 fractions delivering 3 Gy each, administered twice daily (BID) with an inter-fraction interval of at least 6 h). Treatment efficacy was assessed based on local control rates, toxicity (CTCAE criteria), and cosmetic outcomes. : Eight patients were considered. The most common tumor site was the nose (seven patients, 87.5%), followed by the upper lip. Tumors were either primary (three patients, 37.5%) or residual/recurrent after previous surgery with involved margins (five patients, 62.5%). The median follow-up was 6 months (range: 1-19 months). Clinical local control was achieved in all cases, with persistent alteration at dermoscopy in one patient six months after the completion of treatment. Acute toxicities were minimal, with two patients developing grade 3 skin toxicity, which resolved within 1-3 months with topical management. Cosmetic outcomes were favorable across all patients. : HDR-IRT is a well-tolerated, effective, and cosmetically favorable treatment for midface BCC. Our institutional experience supports its use as an alternative to surgery in cosmetically sensitive areas and in selected patients/lesions unfit for surgery. Endocavitary implants appear to be an effective option to cover the full thickness nasal wall without resorting to interstitial implants.
高剂量率(HDR)介入放射治疗(IRT)是治疗面中部基底细胞癌(BCC)的一种有价值的替代方法,尤其是在存在与手术相关的美学或功能问题时。这项回顾性研究考察了在我们机构接受HDR-IRT治疗的患者的临床结果。:组织学确诊为面中部BCC的患者根据肿瘤特征,采用浅表、组织间或腔内植入物进行HDR-IRT治疗。分割方案根据肿瘤位置进行调整:脸颊/唇部每天两次,分9次给予45 Gy;鼻子部位分14次给予44 Gy(第一次和最后一次各给予4 Gy,每天一次,其余12次各给予3 Gy,每天两次(BID),分次间隔至少6小时)。基于局部控制率、毒性(CTCAE标准)和美容效果评估治疗疗效。:共纳入8例患者。最常见的肿瘤部位是鼻子(7例患者,87.5%),其次是上唇。肿瘤为原发性(3例患者,37.5%)或先前手术切缘阳性后的残留/复发性肿瘤(5例患者,62.5%)。中位随访时间为6个月(范围:1 - 19个月)。所有病例均实现临床局部控制,1例患者在治疗完成6个月后皮肤镜检查仍有持续性改变。急性毒性反应轻微,2例患者出现3级皮肤毒性,经局部处理在1 - 3个月内消退。所有患者的美容效果均良好。:HDR-IRT是一种耐受性良好、有效且美容效果良好的面中部BCC治疗方法。我们机构的经验支持其在美容敏感区域以及某些不适合手术的患者/病变中作为手术替代方法使用。腔内植入物似乎是一种有效的选择,可覆盖整个鼻壁厚度而无需采用组织间植入物。